American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021
Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Caballero-Marcos Aránzazu, Salcedo Magdalena, Alonso-Fernández Roberto, Rodríguez-Perálvarez Manuel, Olmedo María, Graus Morales Javier, Cuervas-Mons Valentín, Cachero Alba, Loinaz-Segurola Carmelo, Iñarrairaegui Mercedes, Castells Lluís, Pascual Sonia, Vinaixa-Aunés Carmen, González-Grande Rocío, Otero Alejandra, Tomé Santiago, Tejedor-Tejada Javier, Álamo-Martínez José María, González-Diéguez Luisa, Nogueras-Lopez Flor, Blanco-Fernández Gerardo, Muñoz-Bartolo Gema, Bustamante Francisco Javier, Fábrega Emilio, Romero-Cristóbal Mario, Martin-Mateos Rosa, Del Rio-Izquierdo Julia, Arias-Milla Ana, Calatayud Laura, Marcacuzco-Quinto Alberto A, Fernández-Alonso Víctor, Gómez-Gavara Concepción, Colmenero Jordi, Muñoz Patricia, Pons José A, Spanish Society of Liver Transplantation (SETH)
Аннотация
The protective capacity and duration of humoral immunity after SARS-CoV-2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case-control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID-19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17-83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03-1.36), and therapy with renin-angiotensin-aldosterone system inhibitors (OR = 7.11, 95% CI: 1.47-34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline.